ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "giant cell arteritis"

  • Abstract Number: 0759 • ACR Convergence 2024

    Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media

    Makoto Sugihara1, Nobumasa Watanabe2, Yuichiro Hara2, Yasumasa Nishito3, Mai Kounoe4, Kazunari Sekiyama4, Eisuke Takamasu5, Naofumi Chinen6, Kota Shimada5 and Hideya Kawaji2, 1Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Hokubu Medical Center, Tokyo, Japan, Higashimurayama-shi, Tokyo, Japan, 2Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, 3Center for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, 4Center for Medical Research Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, Setagaya-ku, Tokyo, Japan, 5Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, Fuchu-shi, Tokyo, Japan, 6Department of Rheumatic Diseases, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tokyo, Japan, Tama-shi, Tokyo, Japan

    Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis characterized by inflammatory cell infiltration and destruction of the tunica media. In this study, we…
  • Abstract Number: 1614 • ACR Convergence 2024

    Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry

    Juan Molina-Collada1, Marta Domínguez-Álvaro2, Rafael Benito Melero-Gonzalez3, Eugenio De Miguel4, Maite Silva-Diaz5, Jesús Alejandro Valero6, Ismael Gonzalez7, Julio Sánchez-Martín8, Javier Narvaez-García9, Joan Calvet10, Ivette Casafont-Solé11, José A Román Ivorra12, Selene Labrada-Arrabal13, Margarida Vasques Rocha:14, Carlota L Iñiguez:15, Maria Sagrario Bustabad Reyes16, Cristina Campos-Fernández17, María Alcalde Villar:18, Antonio Juan-Mas19 and Ricardo Blanco-Alonso20, and ARTESER Project Collaborative Group, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3CHU Ourense, O Carballino, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 6Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, 7Complejo Asistencial Universitario de Leon, León, Spain, 8Hospital Universitario 12 de Octubre, Madrid, Spain, 9Hospital Universitario de Bellvitge, Barcelona, Spain, 10Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, 11Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, 12Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, 13Hospital del Mar, Barcelona, Spain, 14Hospital Universitario Araba, Vitoria, Spain, 15Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 16Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, 17Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 18Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 19Hospital Universitari Son Llàtzer, Mallorca, Spain, 20Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
  • Abstract Number: 1635 • ACR Convergence 2024

    Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management

    Matthias Froehlich1, Michael Gernert2, Marc Schmalzing3, Patrick-Pascal Strunz4, Hanna Labinsky5, Thorsten A. Bley6 and Konstanze V. Guggenberger6, 1Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 2Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 3University Hospital Wuerzburg, Würzburg, Germany, 4University hospital of Wuerzburg, Wuerzburg, Germany, 5University Hospital Würzburg, Wuerzburg, Germany, 6University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Imaging techniques such as magnetic resonance imaging (MRI) are a cornerstone for the diagnosis of giant cell arteritis (GCA). In the further course of…
  • Abstract Number: 2650 • ACR Convergence 2024

    Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis

    David Yang1, Quy Cao2, Fang Liu2, Tara McWilliams2, Ryan Rebello3, Madhura Tamhankar2, Shubhasree Banerjee2, Rui Liang2, Robert Kurtz2, Joshua Baker1, Naomi Amudala2, Zhaoyang Fan4, Jae Song2, Peter Merkel1, Jeffrey Morris2 and Rennie Rhee1, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, 3St Joseph’s Hospital and McMaster University, Hamilton, ON, Canada, 4University of Southern California, Los Angeles, CA

    Background/Purpose: There is a need for measures of disease severity for giant cell arteritis (GCA), which may enable identification of high-risk subgroups (e.g., ophthalmic complications)…
  • Abstract Number: 0760 • ACR Convergence 2024

    A Macrophage-smooth Muscle Cell Axis Influences Vascular Remodeling Through Activation of the EGFR Pathway in Giant Cell Arteritis

    Kevin Chevalier1, Léa Dionet1, Paul Breillat1, Margot Poux1, Julien Dang1, Benoit Terris2, Patrick Bruneval3, Luc Mouthon4, Olivia Lenoir1, Tharaux Pierre-Louis1 and Benjamin Terrier5, 1Paris Cardiovascular Research Center, INSERM U970, Paris, France, 2Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, 3Department of Pathology, Hôpital Européen Georges Pompidou, GHU Paris Centre, AP-HP, Université Paris Cité, Paris, France, 4Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 5Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Giant cell arteritis (GCA) is a granulomatous vasculitis affecting large vessels. The role of macrophages and vascular smooth muscle cells (VSMC) appears to be…
  • Abstract Number: 1616 • ACR Convergence 2024

    Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis

    Gaston Ariel Ghio1, Marta Domínguez-Álvaro2, Ricardo Blanco-Alonso3, Santos Castañeda4, Iñigo Hernández-Rodríguez5, Elisa Fernández-Fernández:6, Maite Silva-Diaz7, Joaquin María Belzunegui:8, Clara Moriano9, Julio Sánchez-Martín10, Javier Narvaez-García11, Eva Galindez12, Anne Riveros Frutos13, Francisco Ortiz Sanjuán14, Tarek Carlos Salman Monte:15, Margarida Vasques Rocha:16, Carlota L Iñiguez:17, Alicia García Dorta18, Clara Molina Almela19 and María Alcalde Villar:20, and ARTESER Project Collaborative Group, 1Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 6La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 7Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 8H de Donostia, Donostia-San Sebasti, Spain, 9Hospital León, LEON, Spain, 10Hospital Universitario 12 de Octubre, Madrid, Spain, 11Hospital Universitario de Bellvitge, Barcelona, Spain, 12Hospital Universitario de Cabueñes, Bilbao, Spain, 13Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 14Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, 15Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 16Hospital Universitario Araba, Vitoria, Spain, 17Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 18Rheumatologist, La Laguna, Spain, 19Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 20Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain

    Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
  • Abstract Number: 1637 • ACR Convergence 2024

    Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome

    Pablo Muñoz Martínez1, Claudia Fernandez Ruiz2, Elena Grau García3, Samuel Leal Rodriguez3, José Ivorra-Cortés4, Carmen Riesco Barcena5, Anderson Huaylla Quispe5, Laura Mas Sánchez6, Daniel Ramos Castro5, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado5 and Jose A Román-Ivorra9, 1Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 2Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, 3HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Rheumatology Department. HUP La Fe, Valencia, Spain, 6Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…
  • Abstract Number: 2651 • ACR Convergence 2024

    Vasculitis Associated with VEXAS Syndrome

    Megan Sullivan1, Kambiz Kalantari2, Carolyn Mead-Harvey3, Yael Kusne4, Mrinal Patnaik2, Abhishek Mangaonkar2, Ronald Go2, Daniel Montes2, Kaaren Reichard2, Horatiu Olteanu2, Melanie Bois2, Alexander Hines2, Julio Sartori-Valinotti5, Kenneth Warrington2 and Matthew Koster2, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Scottsdale, AZ, 4Mayo Clinic, Phoenix, AZ, 5Mayo Clinic, Rohester, MN

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
  • Abstract Number: 0761 • ACR Convergence 2024

    An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

    Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

    Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
  • Abstract Number: 1617 • ACR Convergence 2024

    Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission

    Luigi Boiardi1, Pierluigi Macchioni1, Francesco Muratore2, Chiara Marvisi1, Caterina Ricordi1, Annibale Versari1, Giulia Besutti1, Lucia Spaggiari1, Stefania Croci1 and Carlo Salvarani1, 1Azienda Sanitaria Locale, IRCSS, Reggio Emilia, Reggio Emilia, Italy, 2Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…
  • Abstract Number: 1638 • ACR Convergence 2024

    Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis

    Katarina Kmetova1, Emily Chong2, NaveenKumar Somanathapura K3, Kavya Sugur2, Lyndsay Kluge2, Srilakshmi Yalavarthi3, Julia Ford3, Ora Singer4 and Yu Zuo3, 1Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann arbor, Ann arbor, MI, 3University of Michigan, Ann arbor, MI, 4University of Michigan, Huntington Woods, MI

    Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally…
  • Abstract Number: 2652 • ACR Convergence 2024

    Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study

    Geoffroy Peyrac1, Natalie Lomba Goncalves1, Aïcha Kante2, Patrice Cacoub3, Karim Sacré4, David Saadoun5, Thomas Papo4, Jean-François Alexandra6, Valentin Pagis7, Venceslas Bourdin1, Pascal Richette8, Arnaud Vanjak9, Augustin Latourte10, Dikélélé Elessa7, William Bigot1, Ruxandra burlacu7, Karine Champion1, Blanca Amador Borrero7, Amanda Lopes1, Audrey Depond7, Peggy Reiner11, Homa Adle-Biassette12, Aude Couturier13, Philippe Bonnin14, Alexandre Boutigny15, Frédéric Paycha16, Anne Couvelard17, Alexis Régent18, Benjamin Chaigne19, Yann Nguyen20, Agnès lefort20, Olivier Bory21, Elisabeth Aslangul22, stephane mouly1, Damien Sène1, Viet-Thi Tran23 and Cloé Comarmond1, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), 1Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 2Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, 3Sorbonne Université, Paris, 4Université Paris Cité, Paris, France, 5Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, 6INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, 7Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, 8Lariboisière Hospital, Paris, France, 9Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, 10AP-HP, Paris, France, 11Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, 12Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, 13Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, 14Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, 15Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, 16Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, 17Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, 18National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 19Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, 20Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, 21Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, 22Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, 23Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France

    Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
  • Abstract Number: 0762 • ACR Convergence 2024

    Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications

    Helena M Amar Muñoz1, Juan Molina-Collada1, Isabel Castrejon2, irene monjo3, Elisa Fernández-Fernández:4, José María Álvaro-Gracia5 and Eugenio De Miguel6, 1Hospital General Universitario Gregorio Marañón, MADRID, Spain, 2Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3University Hospital La Paz, Madrid, Spain, 4La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 5Hospital Gregorio Marañón, Madrid, Spain, 6Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
  • Abstract Number: 1618 • ACR Convergence 2024

    Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis

    Vivekanand Tiwari1, chih fang2, Emily Campbell3, Katherine loomba2, Nisha Khubchandani2, shikha shah2 and William Rigby4, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth Hitchcock Medical Center, Lebanon, 3Dartmouth Health, Lebanon, NH, 4Dartmouth-Hitchcock, Norwich, VT

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions that often co-occur.1 Approximately half of all patients with GCA experience PMR…
  • Abstract Number: 1640 • ACR Convergence 2024

    ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis

    Eugenio De Miguel1, Iñigo Hernández-Rodríguez2, Maite Silva-Diaz3, Joaquin María Belzunegui:4, Patricia Moya5, Marina Tortosa-Cabañas6, Vanessa Andrea Navarro7, Joan Calvet8, Ivette Casafont-Solé9, Jose A Román-Ivorra10, Selene Labrada-Arrabal11, Margarida Vasques Rocha:12, Carlota L Iñiguez:13, Vanesa Hernández-Hernández14, Cristina Campos-Fernández15, María Alcalde Villar:16, Antonio Juan-Mas17, Francisco-Javier Prado-Galbarro18, Itziar Calvo19, Julio Sánchez-Martín20, Javier Narvaez-García21 and Ricardo Blanco-Alonso22, and ARTESER Project Collaborative Group, 1Hospital Universitario La Paz, Madrid, Spain, 2Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 3Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 4H de Donostia, Donostia-San Sebasti, Spain, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6Hospital Universitario Ramón y Cajal, Madrid, Spain, 7Hospital Moisès Broggi, Sant Joan Despí, Spain, 8Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, 9Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, 10Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain, 11Hospital del Mar, Barcelona, Spain, 12Hospital Universitario Araba, Vitoria, Spain, 13Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 14Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 15Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 16Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 17Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 18Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Unidad Xochimilco,, Mexico, Mexico, 19Hospital Universitario de Basurto, Bilbao, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Universitario de Bellvitge, Barcelona, Spain, 22Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: The diagnosis of giant cell arteritis (GCA) has been guided for years by the ACR 1990 classification criteria but the emergence of the image…
  • 1
  • 2
  • 3
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology